GR1002776B - Anticoagulant effect of the complex attiii/heparin : new screening test for thrombophilic tendency. - Google Patents

Anticoagulant effect of the complex attiii/heparin : new screening test for thrombophilic tendency.

Info

Publication number
GR1002776B
GR1002776B GR960100411A GR960100411A GR1002776B GR 1002776 B GR1002776 B GR 1002776B GR 960100411 A GR960100411 A GR 960100411A GR 960100411 A GR960100411 A GR 960100411A GR 1002776 B GR1002776 B GR 1002776B
Authority
GR
Greece
Prior art keywords
heparin
ratio
abnormal
attiii
factor
Prior art date
Application number
GR960100411A
Other languages
Greek (el)
Inventor
Original Assignee
.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by . filed Critical .
Publication of GR1002776B publication Critical patent/GR1002776B/en

Links

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/86—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving blood coagulating time or factors, or their receptors

Abstract

A novel and useful method for checking the efficacy of the complex ATTIII/heparin is disclosed and claimed herein. It is based on the performance of two APTT clotting times (the one with the addition of a mixture of ATTIII/heparin, and the other with the addition of buffer) and on the calculation of their ratio. 236 subjects (86 healthy controls and 150 thrombophilic patients) have been studied. To all these patients we applied APTT, PT, and a PC-resistance with classic methods, while the mutation Leiden of the factor V was checked with PCR based method. All the clotting, times were calculated with the fibrin-timer of the Behring. We determined the reproducibility (CV=1.9-3.5 %) and the reference limits of the method (2.8 +- 0.70, and values less than 1,45 were arbitrary defined as abnormal, with a possibility of mistake 5%). We found only one healthy control with abnormal ratio, none with abnormal a PC-resistance ratio and none with factor V Leiden mutation, while 16 thrombophiliacs had abnormal ratio. Some of them corrected their ratio after the dilution of their plasma with normal plasma or purified factor IX or Xa. In conclusion, the ATIII/heparin resistance test reveals new causes of thrombophilia. Its correction with the addition of purified factors leads to the search of new mutations to these factors.
GR960100411A 1996-12-02 1996-12-02 Anticoagulant effect of the complex attiii/heparin : new screening test for thrombophilic tendency. GR1002776B (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
GR96100411 1996-12-02

Publications (1)

Publication Number Publication Date
GR1002776B true GR1002776B (en) 1997-09-26

Family

ID=10942565

Family Applications (1)

Application Number Title Priority Date Filing Date
GR960100411A GR1002776B (en) 1996-12-02 1996-12-02 Anticoagulant effect of the complex attiii/heparin : new screening test for thrombophilic tendency.

Country Status (1)

Country Link
GR (1) GR1002776B (en)

Citations (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2583881A1 (en) * 1985-06-21 1986-12-26 Girolami Antoine Method and solution for determining the Howell times and performing heparin tolerance tests
EP0217768A2 (en) * 1985-09-05 1987-04-08 E. Thye Yin Method and compositions for heparin assays
WO1990011368A1 (en) * 1989-03-21 1990-10-04 Proksch Gary J Factor sensitive reagent for testing of blood coagulation
WO1991001383A1 (en) * 1989-07-14 1991-02-07 Michigan State University Method for diagnosing blood clotting disorders
EP0570356A1 (en) * 1992-05-15 1993-11-18 IMMUNO Aktiengesellschaft Reagent for the determination of the activated partial thromboplastin time (aPII)
WO1995012817A1 (en) * 1992-06-08 1995-05-11 Research Corporation Technologies, Inc. Method for measuring heparin

Patent Citations (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2583881A1 (en) * 1985-06-21 1986-12-26 Girolami Antoine Method and solution for determining the Howell times and performing heparin tolerance tests
EP0217768A2 (en) * 1985-09-05 1987-04-08 E. Thye Yin Method and compositions for heparin assays
WO1990011368A1 (en) * 1989-03-21 1990-10-04 Proksch Gary J Factor sensitive reagent for testing of blood coagulation
WO1991001383A1 (en) * 1989-07-14 1991-02-07 Michigan State University Method for diagnosing blood clotting disorders
EP0570356A1 (en) * 1992-05-15 1993-11-18 IMMUNO Aktiengesellschaft Reagent for the determination of the activated partial thromboplastin time (aPII)
WO1995012817A1 (en) * 1992-06-08 1995-05-11 Research Corporation Technologies, Inc. Method for measuring heparin

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
J. FAREED ET AL.: "New perspectives in coagulation testing.", CLINICAL CHEMISTRY., vol. 26, no. 10, September 1980 (1980-09-01), WINSTON US, pages 1380 - 1391, XP002037089 *

Similar Documents

Publication Publication Date Title
Gosselin et al. A comparison of point-of-care instruments designed for monitoring oral anticoagulation with standard laboratory methods
Friedman et al. A spectrum of partially carboxylated prothrombins in the plasmas of coumarin-treated patients
Lawrie et al. The sensitivity and specificity of commercial reagents for the detection of lupus anticoagulant show marked differences in performance between photo-optical and mechanical coagulometers
Vasse et al. Resistance to activated protein C: evaluation of three functional assays
Takahashi Studies on the pathophysiology and treatment of von Willebrand's disease. IV. Mechanism of increased ristocetin-induced platelet aggregation in von Willebrand's disease
Forastiero et al. Evaluation of recently described tests for detection of the lupus anticoagulant
Nyman Von Willebrand factor dependent platelet aggregation and adsorption of factor VIII related antigen by collagen
GR1002776B (en) Anticoagulant effect of the complex attiii/heparin : new screening test for thrombophilic tendency.
Switzer et al. Some effects of calcium on the activation of human factor VIII/von Willebrand factor protein by thrombin
Scully et al. An acquired coagulation inhibitor to factor II
Adcock et al. Evaluation of frozen plasma calibrants for enhanced standardization of the international normalized ratio (INR): a multi-center study
Poller et al. The European Concerted Action on Anticoagulation (ECAA): field studies of coagulometer effects on the ISI of ECAA thromboplastins
Leroy-Matheron et al. Influence of conditions of blood sampling on coagulation activation markers (prothrombin fragment 1+ 2, thrombin-antithrombin complexes and D-dimers) measurements
Boudaoud et al. Endothelial fibrinolytic reactivity and the risk of deep venous thrombosis after spinal cord injury
Özkayın et al. Hypercoagulability risk factors in children with minimal change disease and the protective role of protein-C activity
Brien et al. Discrepant results in INR testing
De Mitrio et al. Influence of factor VIII/von Willebrand complex on the activated protein C-resistance phenotype and on the risk for venous thromboembolism in heterozygous carriers of the factor V Leiden mutation
US6051434A (en) Activated protein C resistance test
Caron et al. A blinded in vitro study with Refacto® mock plasma samples: similar FVIII results between the chromogenic assay and a one‐stage assay when using a higher cephalin dilution
Takahashi et al. Profile of blood coagulation and fibrinolysis in chronic myeloproliferative disorders
Hemker et al. Determination of the levels of unfractionated and low-molecular-weight heparins in plasma: their effect on thrombin-mediated feedback reactions in vivo
Andreasen Automated two-stage assay for determination of antithrombin III with a centrifugal analyzer
DE69916816T2 (en) IMPROVED BLOOD CLUTTER TEST
Lindhoff-Last et al. MIXCON-LA: a precise, sensitive and specific aPTT-based assay for detection of lupus anticoagulant
Jespersen Monitoring plasma antithrombin-III levels during infusion of antithrombin-III concentrate